The insertion took place as part of the company’s ENHANCE clinical trial at the AMCR Institute. AMCR, a clinical research center, focuses on pre-diabetes, type 1, type 2 diabetes and obesity. The study operates under the direction of Dr. Timothy Bailey.
Germantown, Maryland-based Senseonics develops the Eversense platform of long-term, implantable continuous glucose monitors (CGMs). The company’s Eversense E3, a 180-day implantable CGM, received FDA approval in February of last year.
Dr. Francine Kaufman, Senseonics CMO, said expanding to a pediatric population represents a “priority” for the company.
Get the full story at our sister site, Drug Delivery Business News.